A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Protocol No
ECOG-ALCHEMIST-E4512
Principal Investigator
Smitha Menon
Phase
III
Summary
The goal is to conduct one integrated program for screening the target patient (early stage) lung cancer population to identify: EGFR mutations and ALK rearrangements. Patients can then be enrolled on 1 of 2 specific adjuvant trials testing the benefit of adding Erlotinib (EGFR) or Crizotinib (ALK) therapy after standard adjuvant therapy prescribed by the patients' treating physicians.
Description
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: